The Influence of Melatonin Supplementation in the Group of Persons Performing Competitive Sport.

Sponsor
Nicolaus Copernicus University (Other)
Overall Status
Completed
CT.gov ID
NCT03505411
Collaborator
(none)
81
1
35.5

Study Details

Study Description

Brief Summary

The research aims to determine the impact of 30-day supplementation of melatonin on the antioxidative defense mechanisms and the release of markers of oxidative stress and inflammation in rowers and footballers undergoing training of submaximal intensity.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: melatonin supplementation
N/A

Detailed Description

Athlete's body, by its high oxygen demand and increased aerobic metabolism, is exposed to the formation and oxidizing action of reactive oxygen species (ROS). Imbalance between the mechanisms of ROS generation and antioxidative defense of the body can lead to oxidative stress expressed by elevated concentrations of lipid peroxidation products, such as malondialdehyde, isoprostanes (8-iso-PGF2α), oxidized low-density lipoprotein molecules (ox-LDL). The body's defense against ROS includes two systems: nonenzymatic and enzymatic. Small-molecule antioxidants include reduced glutathione (GSH). Due to the presence of -SH groups, glutathione has strong reductive properties. The compound is a substrate for glutathione peroxidase (GSH-Px) which decomposes hydrogen peroxide and organic peroxides. Among antioxidant enzymes are also: superoxide dismutase (Cu-Zn-SOD, scavenges superoxide anion radical), catalase (CAT, reduces hydrogen peroxide), and glutathione reductase (GR, reduces oxidized glutathione). Another well-known small-molecule antioxidant is melatonin, hormone of the pineal gland. It has been demonstrated that this compound can reduce hydrogen peroxide, scavenge hydroxyl radical and deactivate nitric oxide radical.

Another manifestation of disruption of homeostasis in the body of a professional athlete are enhanced inflammatory processes. This can be explained by the fact that during physical effort of varied intensity, increased activity of myeloperoxidase and higher levels of mRNA for tumor necrosis factor, interleukin-1 and -6 are observed. Interleukin-6, also known as myokine, is a particularly important marker of intense physical effort released from damaged muscles. Myokine is also the main upregulator of the synthesis of C-reactive protein (CRP) in the liver, hence measuring the concentration of the protein can indicate the intensity of inflammatory processes in an athlete's body. It has been demonstrated that melatonin, in addition to its hormonal and antioxidant properties, can modulate inflammatory processes by reducing the synthesis of proinflammatory cytokines.

Taking into account the multidirectional function of melatonin, it seems interesting to establish the impact of 30-day supplementation of this hormone on the antioxidative defense mechanisms and the release of markers of oxidative stress and inflammation in rowers and footballers undergoing training of submaximal intensity.

Study Design

Study Type:
Interventional
Actual Enrollment :
81 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Actual Study Start Date :
Jan 15, 2010
Actual Primary Completion Date :
Dec 31, 2012
Actual Study Completion Date :
Dec 31, 2012

Arms and Interventions

Arm Intervention/Treatment
Experimental: melatonin, submaximal effort

1 arm 5 mg melatonin 1 hr before bedtime for 30 days

Dietary Supplement: melatonin supplementation

Outcome Measures

Primary Outcome Measures

  1. Measurement of oxidative stress parameters and inflammatory markers concentration before melatonin administration, at baseline. [1 day]

    The study was conducted in football players and rowers and the control group. Samples of blood from the basilic vein were taken once, from both the control group and the athletes at baseline. In blood serum, the ELISA method was used to determine the concentrations of melatonin, isoprostanes (8-iso-PGF2α), anti-ox-LDL antibodies, interleukin-6 and C-reactive protein (CRP). In red blood cells, the concentration of reduced glutathione (GSH), thiobarbituric acid reactive substances (malondialdehyde, MDA) were determined and the activity of glutathione peroxidase (GSH-Px), cytoplasmic superoxide dismutase (SOD-1) and glutathione reductase (GR) were determined.

Secondary Outcome Measures

  1. Changes in oxidative stress parameters and inflammatory markers concentration afer 30 days of melatonin administration in athletes. [30 day]

    After 30 days of melatonin supplementation, samples of blood from the basilic vein were taken only from athletes, once, in the same day. In biochemistry laboratory, in blood serum, the ELISA method was used to determine the concentrations of melatonin, isoprostanes (8-iso-PGF2α), anti-ox-LDL antibodies, interleukin-6 and C-reactive protein (CRP). In red blood cells, the concentration of reduced glutathione (GSH), thiobarbituric acid reactive substances (malondialdehyde, MDA) were determined and the activity of glutathione peroxidase (GSH-Px), cytoplasmic superoxide dismutase (SOD-1) and glutathione reductase (GR) were determined.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • sign informed consent form for participation in the study
Exclusion Criteria:
  • diseases

  • the participants will not be minor and incapacitated persons, soldiers, prisoners and persons dependent in any way from the investigators

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Nicolaus Copernicus University

Investigators

  • Principal Investigator: Jolanta Czuczejko, Department of Positron Emission Tomography and Molcecular Diagnostics, Collegium Medicum of Nicolaus Copernicus University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jolanta Czuczejko, Assistant professor, Nicolaus Copernicus University
ClinicalTrials.gov Identifier:
NCT03505411
Other Study ID Numbers:
  • KB 586/2009
First Posted:
Apr 23, 2018
Last Update Posted:
Apr 23, 2018
Last Verified:
Mar 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jolanta Czuczejko, Assistant professor, Nicolaus Copernicus University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 23, 2018